HOME >> BIOLOGY >> NEWS
Heart has enough oxygen to survive hypothermia, CPR crucial

ic groups and a control group. They exposed one hypothermic group to 15C (59F) for one hour before rewarming. They exposed the second group to 15C, but for five hours. The control group was kept at normal temperature, 37C (98.6F). The researchers followed the hemodynamic changes during hypothermia and rewarming and later examined the rats' heart cells.

When core body temperature was lowered to 15C, both hypothermic groups experienced a similar reduction in circulating blood volume. And both showed that the physiological mechanisms that help transport oxygen and help unload oxygen from hemoglobin were working. "As a consequence, oxygen supply was not a limiting factor for survival in the present experiments," the authors wrote.

The rats in the one-hour group spontaneously normalized their blood pressure, cardiac output and heart rate after they were rewarmed, Tveita noted. However, the rats in the five-hour group, which were significantly more likely to experience heart failure during rewarming, experienced substantial lowering of cardiac output and other cardiac functions.

"We conclude that the heart failure we see after rewarming is not due to a lack of oxygen supply or oxygen transportation because unloading of oxygen at the cell level from hemoglobin is functioning," Tveita stated. Thus, it appears that the problem comes as a result of the lower cardiac output, he added.

"Thus, efforts aimed at elevating cardiac output in this phase seem advisable in order to optimize oxygen supply, reperfuse (restore blood flow to) vascular beds (minute blood vessels) and prevent rewarming shock formation," the authors wrote

Source and funding

"Is oxygen supply a limiting factor for survival during rewarming from profound hypothermia?" by Timofei V. Kondratiev, Kristina Flemming, and Mikhail A. Sovershaev, University of Troms, Norway; Eivind S.P. Myhre, Srlandet Hospital, Kristiansand; and Torkjel Tveita, Univer
'"/>

Contact: Christine Guilfoy
cguilfoy@the-aps.org
301-634-7253
American Physiological Society
18-Jul-2006


Page: 1 2 3 4

Related biology news :

1. Hearts of male and female rainbow trout are different
2. Heart failure: Intervention possibilities from imaging programmed cell loss
3. Heart intervention doesnt outweigh medicine in study
4. International Society for Heart and Lung Transplantation 27th Annual Meeting and Scientific Sessions
5. Heart rhythm genes possible factors in SIDS
6. Hearts or tails?
7. Heart smart: new drug improves blood flow
8. Defusing a time bomb: Heart attack risk-detection technology developed at UH
9. Heart failure wall stress drops 38% with moderate thyroid hormone therapy
10. New studies released at the Heart Rhythm Societys Annual Meeting
11. Molecular testing impact: Heart transplant patients benefit from new technology, easier monitoring

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Heart has enough oxygen survive hypothermia CPR crucial

(Date:3/17/2015)... March 17, 2015 Emotient, the leader ... today announced general availability of Emotient Analytics ... the analysis of facial expressions. The system analyzes ... content, products and services. It delivers audience response ... sentiment - as derived from facial evidence of ...
(Date:3/12/2015)... , March 12, 2015 The mascots ... Brenner Children,s Hospital, part of Wake Forest Baptist Medical ... initiative for the 2015 ACC Men,s Basketball Tournament. Young ... with them and getting their autographs. Brenner ... Baptist. It is the only children,s hospital in northwest ...
(Date:3/11/2015)... , March 11, 2015   The Sync ... platform to scientifically measure and harness music to ... real-time biometrics and objective measurements of physiology, enabling ... at scale in large populations. It is designed ... and clinicians perform rigorous studies and accelerate the ...
Breaking Biology News(10 mins):New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3
(Date:3/30/2015)... N.J. , March 30, 2015  New Jersey ... innovation projects in the state of New ... next round of grant funding, announced James M. ... Jersey Health Foundation Research Grants program, an additional $500,000 ... each to fund early stage research projects that demonstrate ...
(Date:3/30/2015)... GERMANTOWN, Md. , March 30, 2015  /PRNewswire/ ... a leader in synthetic biology, and Merck Serono, ... Germany , today announced an exclusive ... commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. ... to develop innovative therapies that modulate the immune ...
(Date:3/30/2015)... , March 30, 2015  Naldemedine, an investigational ... by Shionogi & Co., Ltd., met its primary ... (COMPOSE I) for the treatment of opioid-induced constipation ... receiving opioid therapy. Study results showed that naldemedine ... improved the frequency of spontaneous bowel movement (SBM) ...
(Date:3/29/2015)... 29, 2015  Caris Life Sciences® today ... small cell cervical cancer (SCCC) that shows ... the company,s panomic, comprehensive tumor profiling service, identified ... may explain sensitivities and resistance to common ... certain biomarkers may guide treatment strategies in ...
Breaking Biology Technology:New Jersey Health Foundation Announces An Additional $1 Million To Fund Innovation and Research Grants in New Jersey 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 2Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 3
Cached News: